|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sought to examine the impact of AKI and its predictors in diabetic patients with multivessel coronary artery disease undergoing PCI vs. CABG.
|
31230933 |
2019 |
|
Coronary Artery Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
For 401 patients with stable CAD who were indicated for PCI, baseline hs-cTnI levels were measured before PCI for two times (the average: pre-PCI hs-cTnI) and 10 months after PCI (post-PCI remote hs-cTnI).
|
30600349 |
2019 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twelve (86%) patients underwent PCI for stable coronary artery disease and 2 (14%) had unstable angina.
|
31175527 |
2019 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
They dwell on the 'either/or' decision for selected patients suitable for both treatments, but provide little guidance for the majority of 'real world' patients with comorbidities precluding CABG, or complex coronary heart disease precluding PCI.
|
30846525 |
2019 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The most common causes for the presence of unrevascularized CAD included the presence of chronic total occlusion in the native/graft vessels (49.7%) and diffuse/complex CAD unsuitable for PCI (24.6%).
|
31267799 |
2019 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
As confirmed by our results, FFR and CFR are complementary; they could jointly contribute to better PCI guidance through the CFR-to-FFR ratio in patients with coronary artery disease.
|
30616240 |
2019 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sought to compare long-term outcomes of MV PCI and CABG in patients with severe coronary artery disease (CAD) presenting with NSTE-ACS.
|
30251246 |
2019 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The major indication for PCI was stable CAD, whereas acute coronary syndrome represented 30% of the patients.
|
31730255 |
2019 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Bivariate analysis revealed comparatively reduced statin use among patients without other cardiovascular risk factors including hypertension (63% vs. 39.3%; P < 0.0001) and coronary artery disease (CAD) with or without prior cardiac revascularization (coronary artery bypass grafting [CABG]/percutaneous coronary intervention [PCI]; 75.2% vs. 47.4%; P < 0.0001).
|
28602895 |
2018 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We studied 1316 patients with CAD and preserved renal function (estimated glomerular filtration rate ≥60 mL/min/1.73 m<sup>2</sup>) who underwent their first PCI between 2000 and 2011 and had data available for pre-procedural serum albumin.
|
29289574 |
2018 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Methods:</b> In 582 consecutive patients with stable coronary artery disease (CAD) or acute coronary syndrome (ACS) scheduled for PCI and treated with ASA and Clopidogrel, Prasugrel, or Ticagrelor, SNP analysis for rs12566888, rs2768759, rs41273215, rs3737224, and rs822442 was performed.
|
29867494 |
2018 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We consecutively enrolled: a) 40 patients undergoing PCI of a chronic coronary total occlusion (CTO); b) 26 patients with ST-elevation myocardial infarction (STEMI) undergoing primary PCI (pPCI) of the infarct-related artery (IRA); c) 12 control patients undergoing angiography without significant coronary artery disease (CTRL).
|
29602581 |
2018 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients after myocardial infarction, stroke or therapeutic interventions [such as PCI for coronary artery disease (CAD)] with lower TH levels appear to have increased morbidity and mortality.
|
30069456 |
2018 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results indicate that a person-centered approach is useful in explaining heterogeneity in recovery from PCI, and may enhance personalized medicine in patients with CAD.
|
29704656 |
2018 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The LRP Study is an international, multicenter, prospective cohort study conducted in patients with suspected coronary artery disease (CAD) who underwent cardiac catheterization with possible ad hoc PCI for an index event.
|
28938968 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Potent anti-hypertension may influence the occurrence time of AEs after PCI in patients with coronary heart disease complicated hypertension.
|
28745786 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The GuideLiner-Sleeve Technique: A Novel Technique for High-Risk PCI Using Two Left Main Guides for Orbital Atherectomy of Two-Vessel Calcified Ostial Coronary Artery Disease.
|
29086733 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We enrolled patients with coronary artery disease who underwent PCI with stenting.
|
28915645 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Data of consecutive patients with NSTEMI and MVCAD treated in high-volume PCI center between 2006 and 2012 and included in the prospective registry were divided according to the presence of CTO and analyzed.
|
27888750 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The strongest predictors of use of ECMO, TH, coronary angiogram, and PCI were younger age and the presence of coronary artery disease.
|
28494635 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A literature review was performed for trials studying revascularization, via CABG or PCI, in patients with CAD and LV dysfunction.
|
28707392 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
PCI Choice: Cardiovascular clinicians' perceptions of shared decision making in stable coronary artery disease.
|
28110953 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of coronary revascularisation with PCI and CABG in patients with stable and unstable coronary artery disease (CAD) is well established and there is a general consensus among guidelines as regards the indications for coronary revascularisation.
|
28844035 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a planned sub-analysis of the Rosuvastatin For REduction Of Myocardial DamagE During Coronary AngioplastY (REMEDY) trial, 38 patients with stable CAD on chronic low-dose statin therapy were randomized, in a double-blind, placebo-controlled design, into 4 groups before PCI: i. placebo (n = 11); ii. atorvastatin (80 mg+40 mg, n = 9); iii. rosuvastatin (40 mg twice, n = 9); and iv. rosuvastatin (5 mg) and ezetimibe (10 mg) twice, (n = 9).
|
28394933 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A multicenter collaborative analysis was performed on all consecutive patients with native coronary artery disease undergoing PCI with intravascular imaging-guided BVS implantation.
|
27865187 |
2017 |